Related references
Note: Only part of the references are listed.Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual
Jennifer K. Plichta et al.
ANNALS OF SURGERY (2020)
Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging
Olga Kantor et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system
Esther C. Yoon et al.
BREAST JOURNAL (2019)
Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study
Marissa C. van Maaren et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
Salomon M. Stemmer et al.
NPJ BREAST CANCER (2019)
Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer
Armando E. Giuliano et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer
Anna Weiss et al.
JAMA ONCOLOGY (2018)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System
Mariana Chavez-Macgregor et al.
ONCOLOGIST (2017)
Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology
Elizabeth A. Mittendorf et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry
Salomon M. Stemmer et al.
NPJ BREAST CANCER (2017)
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
Ulrike Nitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis
Omar Abdel-Rahman
BREAST CANCER RESEARCH AND TREATMENT (2017)
Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database
Megan C. Roberts et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Comparison of SEER Treatment Data With Medicare Claims
Anne-Michelle Noone et al.
MEDICAL CARE (2016)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Histologic Grade Remains a Prognostic Factor for Breast Cancer Regardless of the Number of Positive Lymph Nodes and Tumor Size A Study of 161 708 Cases of Breast Cancer From the SEER Program
Arnold M. Schwartz et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
Salomon M. Stemmer et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Physician Survey of the Effect of the 21-Gene Recurrence Score Assay Results on Treatment Recommendations for Patients With Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer
Ruth Oratz et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
